New gene-editing technique raises prospect of engineered embryos

A newer gene-editing method is narrowing a technical gap that has long stood between laboratory research and the prospect of engineered embryos, but the ethical line remains exactly where critics have always put it: human germline editing would pass changes to future generations.

The World Health Organization defines human genome editing as somatic, germline or heritable work, and says germline editing can involve early embryos, gametes or their precursors. After convening a global expert committee in December 2018, WHO said in July 2019 that it would be irresponsible at that time for anyone to proceed with clinical applications of heritable human genome editing. That warning still hangs over the field as researchers report more precise tools and bioethicists argue that technical progress does not settle the deeper question of whether such interventions should ever be used to shape human inheritance.

The scientific case for caution is built on a mixed record. In 2017, Nature reported the first rigorous demonstration that CRISPR could efficiently repair a gene defect in human embryos without introducing new mutations. By 2020, the same journal reported that CRISPR experiments in human embryos could also produce large, unwanted changes to the genome at or near the target site. A 2023 study in Human 8-cell embryos added another layer to the debate, reporting that base editing with FNLS-YE1 could efficiently introduce known preventive variants in human embryos.

That mix of promise and risk is why many experts still describe embryo editing against disease as unsafe and unproven for clinical use. A 2024 Nature article said exactly that, even as newer gene- and base-editing studies have reported precise targeting. A 2024 to 2025 review literature also noted that these newer approaches have been accompanied by mosaicism and potentially pathogenic structural DNA damage, problems that can leave edited embryos biologically uneven or damaged in ways that are not yet acceptable for medicine.

WHO tried to set a global framework in 2021 with two recommendations on human genome editing, emphasizing safety, effectiveness, ethics and governance. The policy argument has only grown sharper as technical precision improves. The question is no longer whether scientists can make the edits look cleaner in a dish, but whether cleaner editing lowers the moral barrier enough to make heritable human genome editing seem usable. For many regulators and ethicists, the answer remains no.